TRAVERE THERAPEUTICS, INC. Litigation Settlement, Expense
TRAVERE THERAPEUTICS, INC. (TVTX) reported Litigation Settlement, Expense of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2020-02-24
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for the quarter ending 2018-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for the quarter ending 2017-12-31 was $625.00K.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for fiscal 2019 was $0.00.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for fiscal 2017 was $2.63M, a 49.64% decline from fiscal 2016.
- TRAVERE THERAPEUTICS, INC. litigation settlement, expense for fiscal 2016 was $5.21M.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-24 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $0.00 derived: sum of 2 quarters · filed 2020-02-24 | $0.00 10-K · filed 2020-02-24 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | ||
| 2017-12-31 | $625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $625.00K derived: sum of 2 quarters · filed 2020-02-24 | $2.63M 10-K · filed 2020-02-24 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-01 | $2.00M 10-Q · filed 2018-11-01 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $5.21M derived: sum of 2 quarters · filed 2019-02-26 | $5.21M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $5.21M 10-Q · filed 2017-11-07 | $5.21M 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $0.00 derived: sum of 2 quarters · filed 2018-07-06 | $0.00 10-K · filed 2018-07-06 | |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | ||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |